miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives

[1]  K. Ghoshal,et al.  Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. , 2018, The Journal of Biological Chemistry.

[2]  Lei Sun,et al.  miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC). , 2016, Molecular bioSystems.

[3]  Wei Liu,et al.  miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1 , 2016, Molecular medicine reports.

[4]  Wei Ma,et al.  Up- regulation of miR-328-3p sensitizes non-small cell lung cancer to radiotherapy , 2016, Scientific Reports.

[5]  R. Ferrarotto,et al.  Checkpoint inhibitors in lung cancer: latest developments and clinical potential , 2016, Therapeutic advances in medical oncology.

[6]  G. Calin,et al.  Targeting microRNAs as key modulators of tumor immune response , 2016, Journal of Experimental & Clinical Cancer Research.

[7]  N. Pavlakis,et al.  Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. , 2016, Epigenomics.

[8]  Rongxia Liao,et al.  Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer , 2016, Tumor Biology.

[9]  Hua Shen,et al.  MicroRNA-137 inhibits tumor growth and sensitizes chemosensitivity to paclitaxel and cisplatin in lung cancer , 2016, Oncotarget.

[10]  V. Vlassov,et al.  Dynamic changes in circulating miRNA levels in response to antitumor therapy of lung cancer , 2016, Experimental lung research.

[11]  W. Cho,et al.  Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer , 2016, International journal of molecular sciences.

[12]  S. Eschrich,et al.  ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer , 2016, PloS one.

[13]  Xiaolong Yan,et al.  Upregulation of microrna‐451 increases the sensitivity of A549 cells to radiotherapy through enhancement of apoptosis , 2015, Thoracic cancer.

[14]  Hsien-Da Huang,et al.  miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database , 2015, Nucleic Acids Res..

[15]  G. Calin,et al.  PDL1 Regulation by p53 via miR-34 , 2015, Journal of the National Cancer Institute.

[16]  Giuseppe Curigliano,et al.  Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. , 2016, Pharmacology & therapeutics.

[17]  A. Jemal,et al.  Lung Cancer Statistics. , 2016, Advances in experimental medicine and biology.

[18]  M. Brighenti.  MicroRNA and MET in lung cancer. , 2015, Annals of translational medicine.

[19]  Joe Y. Chang,et al.  In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation , 2015, Molecular therapy. Nucleic acids.

[20]  Shuhang Wang,et al.  Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation , 2015, Journal of Hematology & Oncology.

[21]  Klaus Pantel,et al.  Data Normalization Strategies for MicroRNA Quantification. , 2015, Clinical chemistry.

[22]  B. Kalionis,et al.  Role of Exosomal Noncoding RNAs in Lung Carcinogenesis , 2015, BioMed research international.

[23]  G. Calin,et al.  Progresses towards safe and efficient gene therapy vectors , 2015, Oncotarget.

[24]  L. Crinò,et al.  miRNAs and resistance to EGFR—TKIs in EGFR-mutant non-small cell lung cancer: beyond ‘traditional mechanisms’ of resistance , 2015, Ecancermedicalscience.

[25]  Li Wang,et al.  MicroRNAs level as an initial screening method for early-stage lung cancer: a bivariate diagnostic random-effects meta-analysis. , 2015, International journal of clinical and experimental medicine.

[26]  Xiaoping Liu,et al.  MicroRNA-486 as a Biomarker for Early Diagnosis and Recurrence of Non-Small Cell Lung Cancer , 2015, PloS one.

[27]  G. Reid,et al.  Abstract 3976: Targeted delivery of a synthetic microRNA-based mimic as an approach to cancer therapy , 2015 .

[28]  A. Rossi,et al.  Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application , 2015, Therapeutic advances in medical oncology.

[29]  G. Calin,et al.  MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients , 2015, British Journal of Cancer.

[30]  Alessandro Laganà,et al.  MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC , 2015, Proceedings of the National Academy of Sciences.

[31]  M. Figlerowicz,et al.  High copy number variation of cancer-related microRNA genes and frequent amplification of DICER1 and DROSHA in lung cancer , 2015, Oncotarget.

[32]  C. Croce,et al.  A set of NF-κB–regulated microRNAs induces acquired TRAIL resistance in Lung cancer , 2015, Proceedings of the National Academy of Sciences.

[33]  Massimo Bellomi,et al.  miR-Test: a blood test for lung cancer early detection. , 2015, Journal of the National Cancer Institute.

[34]  Christina Backes,et al.  Longitudinal study on circulating miRNAs in patients after lung cancer resection , 2015, Oncotarget.

[35]  Z. Ling,et al.  Circulating miRNAs is a potential marker for gefitinib sensitivity and correlation with EGFR mutational status in human lung cancers. , 2015, American journal of cancer research.

[36]  Paola Tiberio,et al.  Challenges in Using Circulating miRNAs as Cancer Biomarkers , 2015, BioMed research international.

[37]  B. Chan,et al.  Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. , 2015, Translational lung cancer research.

[38]  Gopal Chakrabarti,et al.  MiR-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis. , 2015, Cellular signalling.

[39]  Juan Zhao,et al.  Clinical use of microRNAs as potential non‐invasive biomarkers for detecting non‐small cell lung cancer: A meta‐analysis , 2015, Respirology.

[40]  G. Dworacki,et al.  Exosomes – Structure, Biogenesis and Biological Role in Non‐Small‐Cell Lung Cancer , 2015, Scandinavian journal of immunology.

[41]  F. Slack,et al.  A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer , 2014, Oncogene.

[42]  C. Rudin,et al.  Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[43]  Haiquan Chen,et al.  Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives , 2014, OncoTargets and therapy.

[44]  Lixia Diao,et al.  Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression , 2014, Nature Communications.

[45]  O. Fortunato,et al.  Therapeutic Use of MicroRNAs in Lung Cancer , 2014, BioMed research international.

[46]  M. Provencio,et al.  Different exosome cargo from plasma/bronchoalveolar lavage in non‐small‐cell lung cancer , 2014, Genes, chromosomes & cancer.

[47]  A. Mathelier,et al.  The Potential of MicroRNAs in Personalized Medicine against Cancers , 2014, BioMed research international.

[48]  F. Hirsch,et al.  MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type , 2014, Oncotarget.

[49]  Zhonghan Li,et al.  Therapeutic targeting of microRNAs: current status and future challenges , 2014, Nature Reviews Drug Discovery.

[50]  S. Lawler,et al.  MicroRNAs in cancer: biomarkers, functions and therapy. , 2014, Trends in molecular medicine.

[51]  T. Tuschl,et al.  Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers , 2014, Proceedings of the National Academy of Sciences.

[52]  S. Kauppinen,et al.  Development of microRNA therapeutics is coming of age , 2014, EMBO molecular medicine.

[53]  H. Hermeking,et al.  The p53/miR-34 axis in development and disease. , 2014, Journal of molecular cell biology.

[54]  Yijiang Chen,et al.  Low expression of let-7 predicts poor prognosis in patients with multiple cancers: a meta-analysis , 2014, Tumor Biology.

[55]  Gopal Chakrabarti,et al.  miR-17-5p Downregulation Contributes to Paclitaxel Resistance of Lung Cancer Cells through Altering Beclin1 Expression , 2014, PloS one.

[56]  L. Paz-Ares,et al.  MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD , 2014, European Respiratory Journal.

[57]  V. Valentini,et al.  Role of MicroRNA in Response to Ionizing Radiations: Evidences and Potential Impact on Clinical Practice for Radiotherapy , 2014, Molecules.

[58]  C. la Vecchia,et al.  Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  G. Calin,et al.  Clinical relevance of circulating cell-free microRNAs in cancer , 2014, Nature Reviews Clinical Oncology.

[60]  Hui-Kuan Lin,et al.  Novel insights into the role of microRNA in lung cancer resistance to treatment and targeted therapy. , 2014, Current cancer drug targets.

[61]  Fumihiro Tanaka,et al.  Recurrence after surgery in patients with NSCLC. , 2014, Translational lung cancer research.

[62]  L. Trusolino,et al.  Targeting the MET gene for the treatment of non-small-cell lung cancer. , 2014, Critical reviews in oncology/hematology.

[63]  S. Ren,et al.  MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. , 2014, Lung cancer.

[64]  M. Stoffel,et al.  Miravirsen (SPC3649) can inhibit the biogenesis of miR-122 , 2013, Nucleic acids research.

[65]  J. Chorostowska-Wynimko,et al.  [Current methods to detect EGFR gene mutations as predictive factor for targeted therapies in non-small cell lung cancer - is there a "golden standard" in diagnostics?]. , 2014, Pneumonologia i alergologia polska.

[66]  B. Qian,et al.  Circulating MicroRNAs in Relation to EGFR Status and Survival of Lung Adenocarcinoma in Female Non-Smokers , 2013, PloS one.

[67]  D. Tang,et al.  microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation , 2013, Medical Oncology.

[68]  M. Fabbri,et al.  MicroRNAs and other non-coding RNAs as targets for anticancer drug development , 2013, Nature Reviews Drug Discovery.

[69]  Marta Di Nicola,et al.  microRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[70]  D. Pardoll,et al.  Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer , 2013, Cancer Immunology Research.

[71]  A. Bouchie.  First microRNA mimic enters clinic , 2013, Nature Biotechnology.

[72]  Robert Brian Jenkins,et al.  Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[73]  W. Ding,et al.  Intercellular Communication by Exosome-Derived microRNAs in Cancer , 2013, International journal of molecular sciences.

[74]  C. Croce,et al.  MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer , 2013, PloS one.

[75]  M. Fabbri.  MicroRNAs and cancer: towards a personalized medicine. , 2013, Current molecular medicine.

[76]  M. Schipper,et al.  Serum miRNA signature to identify a patient’s resistance to high-dose radiation therapy for unresectable non-small cell lung cancer. , 2013 .

[77]  Andrea Sottoriva,et al.  The shaping and functional consequences of the microRNA landscape in breast cancer , 2013, Nature.

[78]  E. Chuang,et al.  MicroRNA-449a Enhances Radiosensitivity in CL1-0 Lung Adenocarcinoma Cells , 2013, PloS one.

[79]  Zhihua Liu,et al.  Effects of Common Polymorphism rs11614913 in Hsa-miR-196a2 on Lung Cancer Risk , 2013, PloS one.

[80]  Bing Feng,et al.  Let-7c Governs the Acquisition of Chemo- or Radioresistance and Epithelial-to-Mesenchymal Transition Phenotypes in Docetaxel-Resistant Lung Adenocarcinoma , 2013, Molecular Cancer Research.

[81]  A. Linē,et al.  Cell‐free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer , 2013, Genes, Chromosomes and Cancer.

[82]  L. J. Lee,et al.  Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer , 2013, Molecular therapy. Nucleic acids.

[83]  W. Mao,et al.  Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy , 2012, Acta Pharmacologica Sinica.

[84]  J. Tong,et al.  Ectopic expression of miR-34a enhances radiosensitivity of non-small cell lung cancer cells, partly by suppressing the LyGDI signaling pathway , 2013, Journal of radiation research.

[85]  T. Ried,et al.  MicroRNA-24 regulates XIAP to reduce the apoptosis threshold in cancer cells , 2012, Oncogene.

[86]  R. Vadigepalli,et al.  MicroRNA Profiling in Lung Cancer Reveals New Molecular Markers for Diagnosis , 2012, Acta Cytologica.

[87]  Dai Zhang,et al.  MirSNP, a database of polymorphisms altering miRNA target sites, identifies miRNA-related SNPs in GWAS SNPs and eQTLs , 2012, BMC Genomics.

[88]  Barbara Burwinkel,et al.  Extracellular miRNAs: the mystery of their origin and function. , 2012, Trends in biochemical sciences.

[89]  F. Slack,et al.  miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. , 2012, Cancer research.

[90]  Yi Tie,et al.  miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. , 2012, Lung cancer.

[91]  B. Zhivotovsky,et al.  miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence , 2012, British Journal of Cancer.

[92]  Baorui Liu,et al.  Cell-Free MicroRNA Expression Profiles in Malignant Effusion Associated with Patient Survival in Non-Small Cell Lung Cancer , 2012, PloS one.

[93]  Xiao-guang Liu,et al.  Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients , 2012, Medical Oncology.

[94]  A. Bader.  miR-34 – a microRNA replacement therapy is headed to the clinic , 2012, Front. Gene..

[95]  Long-Bang Chen,et al.  MicroRNA‐200b reverses chemoresistance of docetaxel‐resistant human lung adenocarcinoma cells by targeting E2F3 , 2012, Cancer.

[96]  A. Keller,et al.  MicroRNA expression changes after lung cancer resection , 2012, RNA biology.

[97]  M. Mayr,et al.  Analytical challenges and technical limitations in assessing circulating MiRNAs , 2012, Thrombosis and Haemostasis.

[98]  E. Ojopi,et al.  Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients , 2012, Clinics.

[99]  Bing Feng,et al.  MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. , 2012, Cancer letters.

[100]  K. Zen,et al.  Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers , 2012, Medicinal research reviews.

[101]  Michael F. Ochs,et al.  Serum microRNA Biomarkers for Detection of Non-Small Cell Lung Cancer , 2012, PloS one.

[102]  Stefan Wiemann,et al.  Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer , 2012, Molecular systems biology.

[103]  E. Giovannetti,et al.  Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. , 2012, Critical reviews in oncology/hematology.

[104]  J. Sun,et al.  EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers , 2011, Nature Medicine.

[105]  A. Bader,et al.  Developing therapeutic microRNAs for cancer , 2011, Gene Therapy.

[106]  F. Gao,et al.  Expression of P-gp, MRP, LRP, GST-π and TopoIIα and intrinsic resistance in human lung cancer cell lines. , 2011, Oncology reports.

[107]  B. Zetter,et al.  miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo , 2011, Oncogene.

[108]  I. Kim,et al.  microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[109]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[110]  Bo Yu,et al.  MicroRNA delivery by cationic lipoplexes for lung cancer therapy. , 2011, Molecular pharmaceutics.

[111]  F. Slack,et al.  Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[112]  B. Burwinkel,et al.  Characterization of extracellular circulating microRNA , 2011, Nucleic acids research.

[113]  F. Fan,et al.  Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer. , 2011, Lung cancer.

[114]  Donglei Liu,et al.  MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2 , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[115]  Fiona A. Stewart,et al.  Strategies to improve radiotherapy with targeted drugs , 2011, Nature Reviews Cancer.

[116]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[117]  Ugo Pastorino,et al.  MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer , 2011, Proceedings of the National Academy of Sciences.

[118]  K. Jażdżewski,et al.  MicroRNAs in thyroid cancer. , 2011, The Journal of clinical endocrinology and metabolism.

[119]  Dieter Jocham,et al.  A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. , 2010, Urologic oncology.

[120]  Jessica A. Weber,et al.  The microRNA spectrum in 12 body fluids. , 2010, Clinical chemistry.

[121]  Leigh-Ann MacFarlane,et al.  MicroRNA: Biogenesis, Function and Role in Cancer , 2010, Current genomics.

[122]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[123]  B. Cho,et al.  Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells. , 2010, Cancer letters.

[124]  X. Chen,et al.  Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions , 2010, BMC Cancer.

[125]  Ali M. Ardekani,et al.  The Role of MicroRNAs in Human Diseases , 2010, Avicenna journal of medical biotechnology.

[126]  K. Kelnar,et al.  Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. , 2010, Cancer research.

[127]  G. Calin,et al.  Non-coding RNAs: Identification of Cancer-Associated microRNAs by Gene Profiling , 2010, Technology in cancer research & treatment.

[128]  Xi Chen,et al.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  Muneesh Tewari,et al.  Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). , 2010, Methods.

[130]  N. Kosaka,et al.  microRNA as a new immune-regulatory agent in breast milk , 2010, Silence.

[131]  L. Marks,et al.  Timing of Local and Distant Failure in Resected Lung Cancer: Implications for Reported Rates of Local Failure , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[132]  Eugene Berezikov,et al.  Expression patterns of intronic microRNAs in Caenorhabditis elegans , 2010, Silence.

[133]  Yingdong Zhao,et al.  MicroRNA Expression Differentiates Histology and Predicts Survival of Lung Cancer , 2010, Clinical Cancer Research.

[134]  F. Slack,et al.  Regression of murine lung tumors by the let-7 microRNA , 2009, Oncogene.

[135]  Feng Bing,et al.  Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1) , 2009, Journal of cellular and molecular medicine.

[136]  Bernat Gel,et al.  miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. , 2009, Carcinogenesis.

[137]  C. Croce.  Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[138]  Alexander Pertsemlidis,et al.  Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. , 2009, Genes & development.

[139]  N. Park,et al.  Salivary microRNA: Discovery, Characterization, and Clinical Utility for Oral Cancer Detection , 2009, Clinical Cancer Research.

[140]  S. Rosenberg,et al.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. , 2009, Blood.

[141]  S. D. Selcuklu,et al.  miR-21 as a key regulator of oncogenic processes. , 2009, Biochemical Society transactions.

[142]  A. Schetter,et al.  MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers , 2009, Proceedings of the National Academy of Sciences.

[143]  D. Beer,et al.  MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. , 2009, Cancer research.

[144]  Noam Shomron,et al.  MicroRNA-Biogenesis and Pre-mRNA Splicing Crosstalk , 2009, Journal of biomedicine & biotechnology.

[145]  Dror Berel,et al.  Expression Signatures of Metastatic Capacity in a Genetic Mouse Model of Lung Adenocarcinoma , 2009, PloS one.

[146]  Erin K Hanson,et al.  Identification of forensically relevant body fluids using a panel of differentially expressed microRNAs. , 2009, Analytical biochemistry.

[147]  Hongbing Shen,et al.  A Functional Genetic Variant in microRNA-196a2 Is Associated with Increased Susceptibility of Lung Cancer in Chinese , 2009, Cancer Epidemiology Biomarkers & Prevention.

[148]  Shaker A Mousa,et al.  Nanoparticles and cancer therapy: A concise review with emphasis on dendrimers , 2009, International journal of nanomedicine.

[149]  Douglas D. Taylor,et al.  Exosomal microRNA: a diagnostic marker for lung cancer. , 2008, Clinical lung cancer.

[150]  Charles R. Martin.  How we got here, where we are going and being a cog in something turning. , 2009, Nanomedicine.

[151]  P. Comoglio,et al.  MicroRNAs impair MET-mediated invasive growth. , 2008, Cancer research.

[152]  Tasneem Motiwala,et al.  Down-regulation of Micro-RNA-1 (miR-1) in Lung Cancer , 2008, Journal of Biological Chemistry.

[153]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[154]  Yariv Yogev,et al.  Serum MicroRNAs Are Promising Novel Biomarkers , 2008, PloS one.

[155]  D. Bartel,et al.  The impact of microRNAs on protein output , 2008, Nature.

[156]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[157]  Hongbing Shen,et al.  Genetic variants of miRNA sequences and non-small cell lung cancer survival. , 2008, The Journal of clinical investigation.

[158]  C. Croce,et al.  MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer , 2008, Oncogene.

[159]  F. Slack,et al.  The let-7 microRNA reduces tumor growth in mouse models of lung cancer , 2008, Cell cycle.

[160]  Phillip A Sharp,et al.  Suppression of non-small cell lung tumor development by the let-7 microRNA family , 2008, Proceedings of the National Academy of Sciences.

[161]  R. Place,et al.  MicroRNA-373 induces expression of genes with complementary promoter sequences , 2008, Proceedings of the National Academy of Sciences.

[162]  Sung-Liang Yu,et al.  MicroRNA signature predicts survival and relapse in lung cancer. , 2008, Cancer cell.

[163]  A. Roses,et al.  Identification of miRNA Changes in Alzheimer's Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways , 2008 .

[164]  Imran Babar,et al.  MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. , 2007, Cancer research.

[165]  J. Chorostowska-Wynimko,et al.  The impact of genetic markers on the diagnosis of lung cancer: a current perspective. , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[166]  F. Slack,et al.  The let-7 microRNA represses cell proliferation pathways in human cells. , 2007, Cancer research.

[167]  Ying Feng,et al.  Supplemental Data P53-mediated Activation of Mirna34 Candidate Tumor-suppressor Genes , 2022 .

[168]  Bruce Stillman,et al.  Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. , 2007, Cancer cell.

[169]  Soon-Cheang Quah,et al.  A Current Perspective , 2007 .

[170]  F. Dosio,et al.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.

[171]  F. Slack,et al.  Oncomirs — microRNAs with a role in cancer , 2006, Nature Reviews Cancer.

[172]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[173]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[174]  Y. Yatabe,et al.  A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. , 2005, Cancer research.

[175]  Chang-Zheng Chen,et al.  MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.

[176]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[177]  F. Slack,et al.  RAS Is Regulated by the let-7 MicroRNA Family , 2005, Cell.

[178]  B. Patterson,et al.  Letter to the editor. , 2018, Journal of professional nursing : official journal of the American Association of Colleges of Nursing.

[179]  B. Cullen.  Transcription and processing of human microRNA precursors. , 2004, Molecular cell.

[180]  B. Cullen,et al.  Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. , 2004, RNA.

[181]  R. Shiekhattar,et al.  The Microprocessor complex mediates the genesis of microRNAs , 2004, Nature.

[182]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[183]  G. Hannon,et al.  Processing of primary microRNAs by the Microprocessor complex , 2004, Nature.

[184]  Sanghyuk Lee,et al.  MicroRNA genes are transcribed by RNA polymerase II , 2004, The EMBO journal.

[185]  M. Fujishiro,et al.  A methylated oligonucleotide induced methylation of GSTP1 promoter and suppressed its expression in A549 lung adenocarcinoma cells. , 2004, Cancer letters.

[186]  Oliver Hobert,et al.  MicroRNAs act sequentially and asymmetrically to control chemosensory laterality in the nematode , 2004, Nature.

[187]  Y. Yatabe,et al.  Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival , 2004, Cancer Research.

[188]  E. Sontheimer,et al.  Distinct Roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA Silencing Pathways , 2004, Cell.

[189]  C. Croce,et al.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[190]  K. Czaplinski,et al.  Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. , 2004, RNA.

[191]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[192]  B. Cullen,et al.  Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. , 2003, Genes & development.

[193]  E. Bertrand,et al.  Human let-7 stem-loop precursors harbor features of RNase III cleavage products. , 2003, Nucleic acids research.

[194]  V. Kim,et al.  The nuclear RNase III Drosha initiates microRNA processing , 2003, Nature.

[195]  T. Rana,et al.  siRNA function in RNAi: a chemical modification analysis. , 2003, RNA.

[196]  C. Burge,et al.  Vertebrate MicroRNA Genes , 2003, Science.

[197]  B. Cullen,et al.  Sequence requirements for micro RNA processing and function in human cells. , 2003, RNA.

[198]  V. Kim,et al.  MicroRNA maturation: stepwise processing and subcellular localization , 2002, The EMBO journal.

[199]  G. Hannon,et al.  C . elegans involved in developmental timing in Dicer functions in RNA interference and in synthesis of small RNA , 2001 .

[200]  A. Pasquinelli,et al.  A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the let-7 Small Temporal RNA , 2001, Science.

[201]  A. Gazdar,et al.  Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.